Trial reportThe Journal of clinical endocrinology and metabolism2010
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.
Trial report in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed.
- Acute Modulation of Circulating Exerkines Responses to a Circuit and Traditional Resistance Training in Young Adults: A Pilot Study.Biomolecules · 2026Trial
- The Short-Term Effect of Prunes in Improving Bone in Men.Nutrients · 2022Trial
- Effects of progesterone therapy on serum sclerostin levels in healthy menopausal women: a 3-month randomized, placebo-controlled clinical trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Trial
- The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Trial
- Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.The Journal of clinical endocrinology and metabolism · 2018Trial
- Trial
- Trial
- Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.Journal of bone and mineral metabolism · 2016Trial
- Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.AIDS research and human retroviruses · 2015Trial
- Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.PloS one · 2015Trial
- Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Trial
- Effect of supplemental vitamin D and calcium on serum sclerostin levels.European journal of endocrinology · 2014Trial
- Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa.The Journal of clinical endocrinology and metabolism · 2014Trial
- Serum sclerostin levels vary with season.The Journal of clinical endocrinology and metabolism · 2014Trial
- Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.Journal of endocrinological investigation · 2012Trial
- Trial
- Trial
- Regulation of circulating sclerostin levels by sex steroids in women and in men.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011Trial
- Mechanisms underlying the waning of osteoanabolic therapy effects in osteoporosis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
contextIntermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear. Sclerostin is an inhibitor of Wnt signaling, and animal studies have demonstrated that PTH suppresses sclerostin production.
objectiveThe objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels.
designProspective study.
settingThe study was conducted at a clinical research unit. PARTICIPANTS AND
interventionsParticipants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women.
main outcome measuresSerum sclerostin levels were measured.
resultsCirculating sclerostin levels decreased significantly in the PTH-treated subjects, from (mean ± SEM) 551 ± 32 to 482 ± 31 pg/ml (-12.7%, P < 0.0001) but did not change in the control women (baseline, 559 ± 34 pg/ml; end point, 537 ± 40 pg/ml, P = 0.207; P = 0.017 for difference in changes between groups). Bone marrow plasma was obtained in a subset of the control and PTH-treated subjects (n = 19 each) at the end of the treatment period, and marrow plasma and peripheral serum sclerostin levels were significantly correlated (R = 0.64, P < 0.0001). Marrow plasma sclerostin levels were 24% lower in PTH-treated compared with control women, but perhaps due to the smaller sample size, this difference was not statistically significant (P = 0.173).
conclusionsCirculating sclerostin levels correlate with bone marrow plasma levels and are reduced by intermittent PTH therapy in postmenopausal women. Further studies are needed to assess the extent to which decreases in sclerostin production contribute to the anabolic skeletal response to PTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.